Consistent with the idea that PR agonists are associated with a good prognosis, it has also been shown that P4 or MPA-activated PR inhibits E2-induced tumor growth and the expression of ER-regulated genes in breast cancer patient-derived xenografts (31). This evidence concerns the gene ESR1 and breast cancer.